Cochrane Review: Exenatide May Improve Motor Function in Parkinson's Disease | Research

The takeaway

Two small RCTs found low-certainty evidence that exenatide improved motor scores in Parkinson's patients, with effects persisting after drug cessation — suggesting possible disease modification.

3.1-5.6 point motor improvement
Exenatide improved MDS-UPDRS Part III scores beyond the minimum clinically important difference in both trials

What the researchers found

Exenatide improved MDS-UPDRS Part III motor scores by 3.1-5.6 points versus controls, with effects persisting after drug cessation, but evidence certainty remains low.

Why it matters

No existing Parkinson's drug slows disease progression. If GLP-1 agonists are truly disease-modifying — as persistence of effects after cessation suggests — it would be a breakthrough in neurodegenerative disease treatment.

The numbers in context

MD -3.10 (MDS-UPDRS III, off-med); adjusted MD -3.5 (exceeds MCID); 62 + 45 patients; low/very low certainty; SAEs unrelated; no HRQoL improvement

How the study worked

Cochrane systematic review of randomized controlled trials comparing GLP-1 receptor agonists versus placebo or no treatment in Parkinson's disease, with GRADE quality assessment.

Who was studied

107 adults with Parkinson's disease across 2 randomized controlled trials of exenatide

What this study cannot tell us

Only 2 small trials available (107 patients total); low to very low certainty evidence; limited follow-up; quality of life and non-motor outcomes unclear; both trials tested exenatide only.

How to read the evidence

Cochrane systematic review with GRADE assessment rated evidence as low to very low certainty due to small sample sizes and limited number of trials.

When this study was published

Published in 2020; several larger GLP-1 agonist trials in Parkinson's have since been initiated or reported results.

The bigger picture

This review set the stage for larger GLP-1 trials in Parkinson's, connecting the diabetes-neurodegeneration pathway to potential disease-modifying therapy for millions of PD patients.

Questions still open

Will larger trials of semaglutide or lixisenatide confirm the motor improvement signal?
Is the persistence of motor benefits after cessation truly disease modification or a prolonged pharmacological effect?
Which Parkinson's patients would benefit most from GLP-1 agonist therapy?

Common questions

Can diabetes drugs treat Parkinson's disease?

Early evidence from two small trials suggests exenatide (a GLP-1 diabetes drug) may improve motor function in Parkinson's, with effects lasting after stopping treatment — but larger trials are needed.

Is exenatide a cure for Parkinson's?

No — current evidence is preliminary and low certainty. However, the persistence of benefits after stopping treatment raises the exciting possibility of disease modification rather than just symptom relief.

Read the original research

GLP-1 receptor agonists for Parkinson's disease.

The Cochrane database of systematic reviews, 7(7), CD012990

View on PubMed ↗Publisher’s paper ↗

Citation

Mulvaney, Caroline A; Duarte, Gonçalo S; Handley, Joel; Evans, David Jw; Menon, Suresh; Wyse, Richard; Emsley, Hedley Ca. (2020). GLP-1 receptor agonists for Parkinson's disease.. The Cochrane database of systematic reviews, 7(7), CD012990. https://doi.org/10.1002/14651858.CD012990.pub2